Venus Medtech (Hangzhou), Inc. Class H (2500) AI Stock Analysis

• Market Cap: HK$1.13B
• Dividend Yield: N/A
• Average Volume (3M): 2.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.13
• Revenue Growth: -8.56%
• EPS Growth: -14.84%
• Country: HK
• Employees: 691
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.34
• Shares Outstanding: 441,010,220
• 10 Day Avg. Volume: 2,133,843
• 30 Day Avg. Volume: 2,483,027
• PEG Ratio: -1.12
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 2.11
• P/FCF Ratio: -55.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: HK$2.50 ▲(7.30% Upside)

The overall stock score is primarily influenced by the company's challenging financial performance and negative valuation metrics. The technical analysis further underscores bearish momentum, with the stock trading below key moving averages and technical indicators suggesting oversold conditions. The absence of earnings call data and notable corporate events means these factors did not influence the score.

Positive Factors

Strong Gross Profit Margin

A strong gross profit margin suggests that Venus Medtech manages its production costs well, which can support profitability once revenue growth stabilizes.

Manageable Debt Load

A manageable debt load provides Venus Medtech with financial flexibility, reducing the risk of financial distress and supporting long-term operations.

Positive Shift in Operating Cash Flow

Improvement in operating cash flow indicates better cash management, which is crucial for sustaining operations and funding growth initiatives.

Negative Factors

Persistent Losses

Ongoing net losses highlight operational challenges and the need for strategic changes to achieve profitability and ensure long-term viability.

Negative Free Cash Flow

Negative free cash flow indicates that Venus Medtech may struggle to fund operations and growth without external financing, posing a risk to sustainability.

Declining Revenue Growth

Declining revenue growth suggests potential issues in market expansion or product demand, which could impact long-term competitiveness and profitability.

Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model

Company Description

Venus Medtech (Hangzhou), Inc. is a leading medical technology company specializing in the development and manufacturing of innovative cardiovascular devices. The company focuses on minimally invasive solutions, particularly in transcatheter aortic valve replacement (TAVR) and other cardiac interventions. With a commitment to advancing healthcare through technology, Venus Medtech operates in the healthcare sector, targeting hospitals and healthcare providers to improve patient outcomes in cardiovascular treatments.

How the Company Makes Money

Venus Medtech generates revenue primarily through the sale of its medical devices, particularly its transcatheter aortic valve products. The company has established key partnerships with hospitals and healthcare systems, enabling it to sell its products directly to medical facilities that perform cardiovascular procedures. Additionally, Venus Medtech may benefit from recurring revenue through maintenance contracts, training services for healthcare professionals, and potential licensing agreements for its proprietary technologies. The growing demand for minimally invasive procedures, along with an increasing patient population requiring cardiovascular care, further bolsters the company's revenue potential.

Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview

Summary

Venus Medtech is facing substantial financial headwinds, characterized by persistent losses and cash flow difficulties. While there are strengths such as a strong gross profit margin and a manageable debt load, the company's inability to achieve profitability and positive cash flow is a significant concern. Continued focus on cost management and revenue growth is essential to improve financial health and ensure long-term sustainability.

Income Statement

The company exhibits a challenging financial situation with consistent net losses over the years. The gross profit margin is relatively strong, indicating effective cost management, but the company is struggling with negative EBIT and EBITDA margins, reflecting significant operational challenges. Revenue growth has been inconsistent, with a decline in the most recent year, highlighting potential issues in market expansion or product demand.

Balance Sheet

The balance sheet shows a strong equity position with a manageable level of debt, as reflected by a favorable debt-to-equity ratio. However, the declining equity ratio over the years and consistent net losses pose risks to financial stability. The company has maintained a solid cash position, but the reduction in cash and equivalents suggests potential liquidity concerns if losses persist.

Cash Flow

Cash flow analysis reveals significant challenges with negative free cash flow over multiple periods, although there is a positive shift in operating cash flow in the latest year. The operating cash flow to net income ratio indicates some improvement, but the company's cash flow generation remains weak overall, raising concerns about its ability to sustain operations without additional financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	427.25M	470.83M	491.37M	406.46M	415.86M	276.05M
Gross Profit	323.97M	367.75M	389.20M	314.00M	324.34M	227.28M
EBITDA	-572.39M	-612.96M	-547.84M	-999.37M	-324.03M	-152.83M
Net Income	-642.59M	-714.31M	-703.75M	-1.06B	-373.64M	-182.87M
Balance Sheet
Total Assets	3.12B	3.25B	4.41B	5.28B	5.11B	4.32B
Cash, Cash Equivalents and Short-Term Investments	293.31M	305.70M	781.64M	1.88B	2.96B	2.75B
Total Debt	493.59M	369.09M	826.19M	899.64M	70.78M	32.76M
Total Liabilities	1.05B	1.04B	1.49B	1.65B	477.61M	461.19M
Stockholders Equity	2.07B	2.21B	2.92B	3.61B	4.55B	3.82B
Cash Flow
Free Cash Flow	-56.51M	-17.82M	-872.93M	-908.23M	-602.08M	-361.05M
Operating Cash Flow	-58.51M	23.74M	-610.02M	-729.46M	-456.92M	-237.00M
Investing Cash Flow	17.23M	-19.90M	-346.86M	-1.07B	-653.04M	-297.94M
Financing Cash Flow	-149.37M	-487.34M	-173.99M	635.14M	1.39B	927.75M

Venus Medtech (Hangzhou), Inc. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2500, the sentiment is Negative. The current price of 2.33 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.92, and below the 200-day MA of 3.26, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 37.96 is Neutral, neither overbought nor oversold. The STOCH value of 13.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2500.

Venus Medtech (Hangzhou), Inc. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2190	58 Neutral	HK$8.47B	47.98	4.99%	0.44%	35.01%	483.73%
6609	55 Neutral	HK$1.92B	41.24	3.84%	―	32.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	43 Neutral	HK$2.70B	509.09	0.22%	―	-4.38%	―
2500	41 Neutral	HK$1.13B	-1.62	-26.80%	―	-8.56%	-14.84%
2216	40 Neutral	HK$1.31B	-10.19	-8.93%	―	-30.60%	28.61%
9996	39 Underperform	€3.87B	-15.77	-11.20%	―	29.25%	9.02%

Venus Medtech (Hangzhou), Inc. Class H Corporate Events

Venus Medtech Completes Patient Enrollment for Cardiovalve Study in Europe

Venus Medtech has successfully completed full patient enrollment for its Cardiovalve TTVR confirmatory clinical study in Europe, marking a significant step towards obtaining CE Mark approval under the EU Medical Device Regulation. This milestone is crucial for the commercialization of Cardiovalve, an innovative system designed to treat tricuspid regurgitation, and demonstrates the company’s commitment to advancing global clinical registration and development of its product portfolio to benefit more patients worldwide.

The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.

Venus Medtech Reports Interim Financial Results Amid Revenue Decline

Venus Medtech (Hangzhou) Inc. reported its unaudited consolidated interim results for the first half of 2025, showing a decrease in revenue by 18.9% compared to the same period in 2024. Despite a reduction in losses before tax by 35.1%, the company continues to face challenges with a loss of RMB 134,772,000 for the period, highlighting ongoing financial pressures and the need for strategic adjustments to improve profitability.

The most recent analyst rating on (HK:2500) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.

Venus Medtech Schedules Board Meeting to Review Interim Results

Venus Medtech (Hangzhou) Inc. has announced a board meeting scheduled for August 28, 2025, to review and approve the interim results for the first half of 2025. The meeting will also consider the recommendation of an interim dividend and address other business matters, potentially impacting the company’s financial strategy and stakeholder interests.